Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines
Details
Publication Year 2024-02-01,Volume 84,Issue #3,Page 353-363
Journal Title
Cancer Research
Publication Type
Review
Abstract
Neoantigen-based cancer vaccines have emerged as a promising immunotherapeutic approach to treat cancer. Nevertheless, the high degree of heterogeneity in tumors poses a significant hurdle for developing a vaccine that targets the therapeutically relevant neoantigens capable of effectively stimulating an immune response as each tumor contains numerous unique putative neoantigens. Understanding the complexities of tumor heterogeneity is crucial for the development of personalized neoantigen-based vaccines, which hold the potential to revolutionize cancer treatment and improve patient outcomes. In this review, we discuss recent advancements in the design of neoantigen-based cancer vaccines emphasizing the identification, validation, formulation, and targeting of neoantigens while addressing the challenges posed by tumor heterogeneity. The review highlights the application of cutting-edge approaches, such as single-cell sequencing and artificial intelligence to identify immunogenic neoantigens, while outlining current limitations and proposing future research directions to develop effective neoantigen-based vaccines.
Publisher
American Association for Cancer Research
Keywords
Humans; *Cancer Vaccines/therapeutic use; Antigens, Neoplasm/genetics; Artificial Intelligence; *Neoplasms/drug therapy; Immunotherapy
Department(s)
Laboratory Research
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-03-13 05:27:12
Last Modified: 2024-03-13 05:27:28

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙